As a countdown to the World Economic Forum’s annual meeting at Davos, we’re profiling all 30 of our fellow 2011 Tech Pioneer award winners. Check our full profile series to learn more.
Molecular Partners is developing new medicines using proteins known as DARPins. DARPins appear in nature as binders or blockers; for example, they might target and block a tumor cell in the human body. DARPins offer advantages over antibodies, the most common kind of proteins used in medicine today. DARPins are smaller, more potent, and more selective, and can reach areas in the body that antibodies can’t, allowing for more effective treatment. Plus, DARPins are cheaper and faster to manufacture than antibodies.
Why it’s cool:
Molecular Partners’ work will create treatments for untreatable diseases–and make existing treatments more effective. The company is developing drugs for ophthamalogy, inflammation, and oncology right now, and will soon move on to other fields. Three cheers for health!